Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2025)

Historic Current Assets for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $922.0 million.

  • Indivior Pharmaceuticals' Current Assets changed N/A to $922.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $922.0 million, marking a year-over-year change of. This contributed to the annual value of $827.0 million for FY2024, which is 3420.84% down from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Current Assets stood at $922.0 million.
  • In the past 5 years, Indivior Pharmaceuticals' Current Assets ranged from a high of $1.4 billion in Q4 2021 and a low of $827.0 million during Q4 2024
  • In the last 5 years, Indivior Pharmaceuticals' Current Assets had a median value of $951.0 million in 2025 and averaged $1.1 billion.
  • Its Current Assets has fluctuated over the past 5 years, first decreased by 15.89% in 2023, then tumbled by 3420.84% in 2024.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Current Assets stood at $1.4 billion in 2021, then dropped by 12.81% to $1.3 billion in 2022, then dropped by 0.16% to $1.3 billion in 2023, then tumbled by 34.21% to $827.0 million in 2024, then increased by 11.49% to $922.0 million in 2025.
  • Its last three reported values are $922.0 million in Q3 2025, $951.0 million for Q2 2025, and $883.0 million during Q1 2025.